Genmab A/S GMAB
OMXCOP · Danimarka · Sağlık Teknolojisi
DKK 2.330,00-13,00 (-%0,55)
Piyasa açık· · DKK · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa açık· · DKK · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Genmab A/S (NASDAQ:GMAB) expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company’s vice president and head of investor relations. Carlsen said
Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the
The consensus analyst Price Target fair value for Genmab has been adjusted to DKK 2,303.24 from DKK 2,453.79, pointing to a slightly lower central target level for the stock. Analysts link this change to a balance of confidence in Genmab’s pipeline, including Epkinly and other key assets, and caution around concentration risks, clinical assumptions and the impact of the reported $3.6b Darzalex patent cliff. As you read on, you will see how these moving pieces shape the evolving analyst...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.